- A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma — Active Not Recruiting • Phase I / Phase II • NCT05421663.
- New dual-targeted CAR-T cell therapy tested in relapsed/refractory B-cell lymphoma and high-risk newly diagnosed DLBCL.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
This is a Phase 1b/2, multicenter, open-label, study of prizloncabtagene autoleucel (prizlo-cel), an autologous dual targeting chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD20 and CD19, for the treatment of adult participants with relapsed or refractory (r/r) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse large B-cell lymphoma (DLBCL). Conditions: Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse Interventions: Prizloncabtagene autoleucel (Prizlo-Cel) Lead Sponsor: Janssen Research & Development, LLC Planned Enrollment: 166 participants